CONTEXTVISION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.3 NOK | -1.56% |
|
-7.08% | -18.18% |
| Apr. 03 | ContextVision Announces New Image Quality Advancements in X-Ray | CI |
| Feb. 16 | Transcript : ContextVision AB, Q4 2023 Earnings Call, Feb 16, 2024 |
| Sales 2024 * | 136M 12.38M | Sales 2025 * | 142M 12.93M | Capitalization | 487M 44.27M |
|---|---|---|---|---|---|
| Net income 2024 * | 23M 2.09M | Net income 2025 * | 24M 2.18M | EV / Sales 2024 * | 3.2 x |
| Net cash position 2024 * | 51.78M 4.7M | Net cash position 2025 * | 46.39M 4.21M | EV / Sales 2025 * | 3.1 x |
| P/E ratio 2024 * |
20.7
x | P/E ratio 2025 * |
20
x | Employees | 40 |
| Yield 2024 * |
6.46% | Yield 2025 * |
7.27% | Free-Float | 34.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on ContextVision AB
More press releases
| 1 day | -1.56% | ||
| 1 week | -7.08% | ||
| Current month | -7.35% | ||
| 1 month | -10.00% | ||
| 3 months | -21.25% | ||
| 6 months | -13.46% | ||
| Current year | -18.18% |
1 week
6.30
6.98
1 month
6.306.98
Current year
6.309.20
1 year
6.309.88
3 years
6.3027.10
5 years
5.0530.90
10 years
1.4430.90
| Managers | Title | Age | Since |
|---|---|---|---|
Gerald Pötzsch
CEO | Chief Executive Officer | 52 | 22-07-31 |
| Director of Finance/CFO | - | 23-08-27 | |
Gunnar Läthén
CTO | Chief Tech/Sci/R&D Officer | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Hedlund
FOU | Founder | 72 | 82-12-31 |
Lars Olof Sandèn
CHM | Chairman | 62 | 21-05-04 |
| Founder | 70 | 82-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 6.3 | -1.56% | 41,502 |
| 24-04-18 | 6.4 | -4.19% | 89,050 |
| 24-04-17 | 6.68 | 0.00% | 1,068 |
| 24-04-16 | 6.68 | +0.60% | 6,929 |
| 24-04-15 | 6.64 | -2.06% | 3,152 |
Real-time Oslo Bors, April 19, 2024 at 10:45 am EDT
More quotes
ContextVision AB is a Sweden-based medical technology software company specialized in image analysis and artificial intelligence. The Company is engaged in the image enhancement market and is a partner to the manufacturers of ultrasound, X-ray and Magnetic Resonance Imaging (MRI) equipment around the world. The Company develops software products, based on proprietary technology and artificial intelligence for image-based applications. ContextVisionâs cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The Company operates through two separate segments: the Business Unit Medical Imaging and the Business Unit Digital Pathology. ContextVision has two subsidiaries: Inify Laboratories AB og ContextVision Inc.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.3
NOK
Average target price
7.5
NOK
Spread / Average Target
+19.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.18% | 44.27M | |
| +3.04% | 32.01B | |
| +7.44% | 6.91B | |
| +15.28% | 3.67B | |
| -10.66% | 3.36B | |
| -26.04% | 1.28B | |
| -40.17% | 1.02B | |
| +0.92% | 903M | |
| -42.60% | 802M | |
| -27.55% | 818M |
- Stock Market
- Equities
- CONTX Stock
